Hartman v. Pocatello Hospital: Mandatory Disclosure of Non‑Testifying Local Standard‑of‑Care Consultants and “General Risk” Foreseeability for Proximate Cause

1. Introduction

In Hartman v. Pocatello Hospital (Idaho Supreme Court, June 1, 2026), the Hartman family brought medical-malpractice claims arising from the prescription, dispensing, and administration of transdermal fentanyl patches to Sheri Hartman, who died days later with “acute fentanyl intoxication” and “fentanyl overdose” listed as causes of death. The defendants included emergency-department providers (Dr. Willis Parmley and PA Amber Schroeder and their group), an orthopedic surgeon (Dr. Stephen Hansen and his clinic), and Portneuf Medical Center (“PMC”), including a claim targeting the hospital pharmacist’s dispensing of the initial patch.

The appeal presented two doctrinally important issues:

  1. Discovery / expert disclosure: whether plaintiffs must disclose the identities of non-testifying local standard-of-care consultants when their testifying out-of-state experts relied “primarily” on a defendant’s deposition testimony to establish familiarity with the local standard of care.
  2. Causation / foreseeability at summary judgment: whether defendants are entitled to summary judgment when plaintiffs do not rebut defense evidence that the precise pharmacokinetic mechanism (e.g., “molecules from the first patch”) could not have persisted until death.

2. Summary of the Opinion

The Idaho Supreme Court:

  • Affirmed the district court’s discovery sanctions striking plaintiffs’ liability experts for failure to timely disclose the identities of non-testifying local standard-of-care experts, reiterating Quigley v. Kemp.
  • Reversed in part the causation summary judgment ruling to the extent it dismissed the claim against PMC (Count II) based on the hospital pharmacist’s alleged negligence, holding that proximate-cause foreseeability turns on the general risk of harm, not the specific mechanism by which harm occurred (citing Orthman v. Idaho Power Co.).
  • Limited remand practically to PMC because plaintiffs’ other claims failed after their liability experts were excluded.
  • Awarded partial attorney fees against plaintiffs under I.C. § 12-121 for pursuing the sanctions/exclusion appeal “frivolously, unreasonably, and without foundation.”

3. Analysis

3.1 Precedents Cited

A. Expert disclosure and discovery sanctions

  • Quigley v. Kemp, 162 Idaho 408, 412, 398 P.3d 141, 145 (2017)
    Role in Hartman: This is the centerpiece. Hartman treats Quigley as establishing that Rule 26(b)(4)(A)(i)’s requirement to disclose “basis and reasons” and “data or other information” considered “fairly encompasses” the names of non-testifying medical experts who provide information concerning the local standard of care. Hartman extends the practical implication: disclosure is required even if the consultant’s input is not the “primary” basis.
  • Phillips v. Eastern Idaho Health Services., Inc., 166 Idaho 731, 463 P.3d 365 (2020)
    Role in Hartman: Plaintiffs invoked Phillips to reframe consultant identity as “ordinary fact discovery” with looser supplementation timing. The Court rejected this, explaining Phillips addressed whether a local consultant could be deposed (requiring “exceptional circumstances”), not whether the consultant’s identity must be disclosed. Hartman clarifies that consultant identity is both (i) discoverable under Rule 26(b)(1)(A) and (ii) required within expert disclosures under Rule 26(b)(4)(A)(i) when relied upon.
  • Easterling v. Kendall, 159 Idaho 902, 367 P.3d 1214 (2016)
    Role in Hartman: Supports that exclusion of experts can be an appropriate Rule 37(c) sanction for failure to comply with expert-disclosure obligations and scheduling orders.
  • Clark v. Klein, 137 Idaho 154, 158 n.1, 45 P.3d 810, 814 n.1 (2002)
    Role in Hartman: Rejects the notion that the defense must first file a motion to compel before seeking exclusion for Rule 26 noncompliance; reinforces trial-court enforcement authority.
  • Gem State Roofing, Inc. v. United Components, Inc., 168 Idaho 820, 829–30, 488 P.3d 488, 497–98 (2021) and State Ins. Fund v. Jarolimek, 139 Idaho 137, 75 P.3d 191 (2003)
    Role in Hartman: Supply the discretionary standard for discovery sanctions and the policy that discovery is not a “game.”
  • Lunneborg v. My Fun Life, 163 Idaho 856, 863, 421 P.3 187, 194 (2018)
    Role in Hartman: Provides the four-part abuse-of-discretion framework applied to sanctions.
  • United States v. Procter & Gamble Co., 356 U.S. 677, 682 (1958) (citing Hickman v. Taylor, 329 U.S. 495, 501 (1947))
    Role in Hartman: Frames discovery’s purpose as avoiding “blind man’s bluff,” supporting broad disclosure expectations.
  • Lands v. Sunset Manor, LP, 173 Idaho 658, 668, 546 P.3d 670, 680 (2024)
    Role in Hartman: Cited for Rule 26(b)(4) disclosure mechanics (“basis and reasons,” “data or other information”).
  • Bybee v. Gorman, 157 Idaho 169, 178, 335 P.3d 14, 23 (2014)
    Role in Hartman: Plaintiffs argued that failing to identify an “anonymous consultant” is not categorically fatal to admissibility under Idaho Code section 6-1013. The Court distinguished admissibility/foundation from discovery sanctions: Bybee does not limit Rule 37(c) sanctions for disclosure failures.
  • Hickman v. Boomers, LLC, 174 Idaho 1048, 1058 n.1, 554 P.3d 99, 109 n.1 (2024)
    Role in Hartman: Supports declining to consider issues raised for the first time at oral argument.

B. Proximate cause, substantial factor, and foreseeability

  • Newberry v. Martens, 142 Idaho 284, 288, 127 P.3d 187, 191 (2005)
    Role in Hartman: Defines proximate cause as including cause-in-fact plus “scope of legal responsibility” (“true proximate cause”).
  • Garcia v. Windley, 144 Idaho 539, 543, 164 P.3d 819, 823 (2007)
    Role in Hartman: Explains the “but for” test when a single possible cause exists.
  • Fussell v. St. Clair, 120 Idaho 591, 595, 818 P.2d 295, 299 (1991)
    Role in Hartman: Anchors the “substantial factor” test where multiple potential causes exist.
  • Orthman v. Idaho Power Co. (Orthman II), 130 Idaho 597, 601, 944 P.2d 1360, 1364 (1997) (discussing Sharp v. W.H. Moore, Inc., 118 Idaho 297, 796 P.2d 506 (1990))
    Role in Hartman: The causation holding turns on Orthman II: foreseeability for proximate cause concerns the general risk of harm, not the specific mechanism by which the harm occurred. The district court erred by focusing on whether molecules from the first patch remained at death (a mechanism-focused inquiry).
  • Orthman v. Idaho Power Co. (Orthman I), 126 Idaho 960, 895 P.2d 561 (1995)
    Role in Hartman: Provides the underlying litigation context for Orthman II.
  • Cramer v. Slater, 146 Idaho 868, 875–76, 204 P.3d 508, 515–16 (2009)
    Role in Hartman: Reinforces that causation is typically for the jury when reasonable minds could differ.
  • Ballard v. Kerr, 160 Idaho 674, 692, 378 P.3d 464, 482 (2016)
    Role in Hartman: Used by analogy to reject imposing “impossible” causation proof requirements (here, tracing fentanyl by patch-specific molecules).

C. Summary judgment and appellate standards

  • Fragnella v. Petrovich, 153 Idaho 266, 271, 281 P.3d 103, 108 (2012)
    Role in Hartman: Sets summary-judgment lens: view facts and inferences in favor of the nonmoving party; “mere scintilla” insufficient.

D. Attorney fees for frivolous appeal

  • Idaho Mil. Hist. Soc'y, Inc. v. Maslen, 156 Idaho 624, 632, 329 P.3d 1072, 1080 (2014)
    Role in Hartman: Supports apportionment of fees to the frivolous portion of an appeal.

3.2 Legal Reasoning

A. The “primary vs. secondary reliance” argument fails under Rule 26’s text and Quigley

The Court framed the consultant-identity issue as a discovery compliance dispute, not a courtroom admissibility fight. It emphasized the text of I.R.C.P. 26(b)(4)(A)(i): expert disclosures must include “a complete statement of all opinions” plus “the basis and reasons” and “the data or other information considered”. From that language, the Court reasoned that:

  • the rule contains no weighting carve-out (no “primary basis” limitation); and
  • if a non-testifying local consultant informed the testifying expert to any degree, identity disclosure is required.

Thus, even if a defendant’s deposition testimony is a major source for “locality” knowledge, consultant identity remains disclosable if consulted. The Court also endorsed strong enforcement: when the failure is not “substantially justified” or “harmless,” I.R.C.P. 37(c)(1) authorizes exclusion of the witness—even if it effectively ends the plaintiff’s case.

B. Causation: the district court improperly demanded mechanism-specific proof

On causation, the Court separated:

  • Cause in fact (actual cause): in a multi-actor medical timeline, apply the substantial factor test, not a strict “but for” persistence-of-molecules inquiry.
  • True proximate cause (legal cause): evaluate whether the harm falls within the general scope of risk that made the conduct negligent.

The district court’s approach—treating as dispositive whether fentanyl from the first patch could have remained in the body at death—functionally required plaintiffs to prove the precise pharmacokinetic mechanism of contribution. That, the Court held, conflicts with Orthman v. Idaho Power Co. (Orthman II), which rejects mechanism-level foreseeability as the summary-judgment yardstick.

Under Hartman, the correct foreseeability question is broader: whether a reasonable provider should have foreseen the general risk of opioid-related harm from dispensing/administration in the patient’s clinical context—not whether it was foreseeable that molecules from a particular patch would still be present days later.

C. Procedural consequence: reversal on causation does not revive dismissed provider claims

Even though causation summary judgment was reversed as to PMC, plaintiffs’ claims against the Emergency Providers and Orthopedic Surgeon remained dismissed because the expert-exclusion sanctions (affirmed) left plaintiffs unable to prove breach of the standard of care. The remand is therefore practically confined to the pharmacist-negligence claim against PMC (Count II), and the Court directed dismissal of the informed-consent claim (Count V) based on plaintiffs’ concession.

3.3 Impact

A. Expert discovery: Idaho reinforces a bright-line disclosure obligation

The decision strengthens (and clarifies) Idaho’s medical-malpractice discovery regime in three ways:

  • No “primary reliance” exception: if a local consultant contributed at all to an out-of-area expert’s locality familiarity, identity disclosure is mandatory.
  • Sanctions are real: exclusion of key experts is affirmed as a proportionate sanction for intentional, prejudicial, unjustified noncompliance with I.R.C.P. 16 and 37.
  • Protective-order strategy is constrained: generalized fears of “retribution” without factual support will not establish “good cause,” and delaying disclosure while seeking protection can be sanctionable.

B. Causation: plaintiffs need not prove the “molecular pathway” to survive summary judgment

For opioid, pharmacology, and other medically complex causation disputes, Hartman reduces the risk that summary judgment becomes a contest over whether plaintiffs can prove a hyper-specific biological mechanism at the dispositive-motion stage. The holding re-centers proximate cause on:

  • whether the defendant’s conduct was a substantial factor in the injury in a multi-cause setting; and
  • whether the injury was within the general foreseeable risk created by the alleged negligence.

C. Appellate practice: fee exposure for weak sanctions appeals

The partial I.C. § 12-121 fee award signals that relitigating settled Rule 26/Quigley obligations using inapposite authority (e.g., Phillips and Bybee as deployed here) can trigger fee shifting, at least as to the frivolous portion of an appeal.

4. Complex Concepts Simplified

  • “Local standard of care” (Idaho Code section 6-1013): in Idaho medical-malpractice cases, plaintiffs generally must show what competent practice looked like in the defendant’s community (or similar communities) at the relevant time, typically through qualified expert testimony.
  • Non-testifying local standard-of-care expert (“consultant”): a local clinician who helps an out-of-area testifying expert learn local practice norms. Even if that consultant never testifies, Hartman holds their identity must be disclosed when relied upon.
  • Rule 26 vs. Rule 37 vs. Rule 16:
    • I.R.C.P. 26 defines what must be disclosed in discovery (including expert disclosures).
    • I.R.C.P. 16 allows scheduling orders with deadlines (including expert disclosure deadlines).
    • I.R.C.P. 37 supplies sanctions when parties violate disclosure duties (including exclusion of witnesses under 37(c)(1)).
  • Cause in fact vs. proximate (legal) cause:
    • Cause in fact asks whether the defendant’s conduct actually contributed to the harm.
    • Proximate cause asks whether the law should hold the defendant responsible for that harm—often framed through foreseeability.
  • “But for” vs. “substantial factor”:
    • But for fits single-cause scenarios (harm would not have happened but for defendant’s act).
    • Substantial factor fits multiple contributing causes (defendant’s act materially contributed even if others also contributed).
  • “General risk of harm” vs. “specific mechanism of injury” foreseeability:
    • General risk: e.g., opioids can cause respiratory depression/overdose under certain conditions.
    • Specific mechanism: e.g., whether fentanyl molecules from Patch #1 were still present on the date of death. Hartman says plaintiffs need not prove foreseeability at that mechanistic level to avoid summary judgment.

5. Conclusion

Hartman v. Pocatello Hospital delivers two primary takeaways for Idaho practice. First, it fortifies a strict expert-disclosure rule: when out-of-area experts consult non-testifying local standard-of-care experts, those consultants’ identities must be disclosed under I.R.C.P. 26(b)(4)(A)(i), regardless of whether the consultation was “primary” or “secondary,” and intentional noncompliance can justify exclusion under I.R.C.P. 37(c)(1). Second, it recalibrates causation analysis at summary judgment: proximate-cause foreseeability turns on the general risk of harm, not the precise biological or pharmacokinetic mechanism by which injury occurred, aligning medical-malpractice causation with Orthman v. Idaho Power Co. (Orthman II).